Jilin Aodong Pharmaceutical Group Co., Ltd. (000623)

Jilin Aodong Pharmaceutical Group Co., Ltd. (000623)

The predecessor of Jilin Aodong Pharmaceutical Group Co., Ltd. was established in 1957 in Yanbian Dunhua Luchang. In 1981, Aodong pharmaceutical factory was established. In March 1993, it was approved by the provincial Commission of physical reform and reform to Jilin Aodong Pharmaceutical Group Co., Ltd. and was listed on Shenzhen Stock Exchange on October 28th, 1996. The company now owns 5 professional pharmaceutical subsidiaries engaged in modern Chinese medicine, biochemistry and phytochemicals, 9 pharmaceutical sales subsidiaries, 8 pharmaceutical supporting subsidiaries, 2 high-end health products companies, 1 highway construction toll company, 1 Aodong International (Hong Kong) industrial limited company, with planting and breeding bases, The industrial chain management mode of "company + standardization base + franchised farmers" has been established, and gradually developed into a holding group listed company which is based on the pharmaceutical industry and developed rapidly in the dual wheel drive mode of "industry + finance". At present, the company is the first largest shareholder of Guangfa Securities Co., Ltd. (Securities abbreviation: Guangfa Securities, securities code: 000776.sz, 1776.hk), and also invests in Liaoning Chengda Co., Ltd. (hereinafter referred to as Liaoning Chengda, securities code: 600739), Shanghai first medical medicine Co., Ltd. (Securities abbreviation: first medicine, securities code: 600833.sh) Jilin Yatai (Group) Co., Ltd. (abbreviated as Yatai group for short), securities code: 600881.sh, Nanjing Pharmaceutical Co., Ltd. (abbreviated as Nanjing medicine, securities code: 600713.sh), Jilin Boya special medical nutrition Technology Co., Ltd.

By the end of 2020, the total assets of the company are 27353457100 yuan, an increase of 1552552200 yuan, an increase of 6.02% over the beginning of the year; The net assets attributable to the shareholders of the listed company amounted to 23353302050 yuan, an increase of RMB 1103522000, an increase of 4.96% over the beginning of the year; The ratio of assets and liabilities was 13.98%; The operating income was RMB 225165100000, a decrease of 83.7286 million yuan, or 27.09% over the same period of the previous year; The total profit achieved was 1716555300 yuan, an increase of 23.38103 million yuan, an increase of 16.00% over the same period of the previous year; The net profit attributable to the shareholders of the listed company was RMB 1708876100, an increase of RMB 305.2357 million, an increase of 21.75%, of which, in 2020, Guangfa Securities realized the net profit attributable to the shareholders of the listed company by RMB 10038134600, and the investment income of the company to Guangfa Securities in the current period was 1777.8 million yuan, an increase of 46.19487 million yuan, an increase of 35.11%.

The company has successively obtained the key high-tech enterprises of the national torch plan, national high-tech enterprises, national innovative enterprises, national intellectual property superiority enterprises, national model harmonious labor relations enterprises, National May 1st Labor Medal, national advanced single in open democratic management of factory affairs, party organization of "double top 100" of national non-public enterprises, 16th session The first prize of the 21st national enterprise management modernization innovation achievement, has been awarded as a class taxpayer for many years, AAA level "contract abiding and credit abiding" unit and many other honors.

After decades of development, the company has created a unique core competitiveness of the enterprise:

Brand advantage: Aodong and Tu trademark is a well-known trademark in China, and it is a valuable intangible asset formed after the establishment of a pharmaceutical factory in the past 40 years after the establishment of the brand, the expansion of the brand and the maintenance of the brand. As the symbol and quality guarantee of the enterprise, Aodong brand has been selected as the "top 500 brand in China" issued by the world brand lab for 17 years. The brand value is RMB 10.464 billion. The company is recognized as an "Jilin old brand" enterprise, which represents reputation, quality and responsibility. At the same time, the company products have won the general recognition of the masses by "excellent quality and reasonable price", and obtained good reputation and reputation.

Quality advantage: since the establishment of pharmaceutical factory, the company has insisted on quality first, and constantly promoted quality change to enhance quality advantage. The company has national enterprise technology center and National Postdoctoral research workstation. The company has formulated internal control standards higher than the national legal standards, established the concept of "quality is the life of enterprises", and strictly controlled the product quality in accordance with the spirit of "craftsman", continuously improved the quality of drugs, made good efforts to ensure that each drug and each drug are safe, reliable and assured. Yanbian pharmaceutical industry has successively won the title of quality benchmark of national industrial enterprises and Jilin quality award; Yanji pharmaceutical industry won Jilin Quality Award; Taonan pharmaceutical industry has won the national high-tech enterprises and Jilin quality awards.

Technical advantages: the company has always adhered to the core values of "focusing on people and focusing on medicine", adhering to the development path of "developing enterprises with science and technology" and "strengthening enterprises with science and technology", and continuously carrying out technological innovation. In the production, the company adopted the whole process online detection and analysis technology to establish the automatic production line of traditional Chinese medicine extraction, and adopted modern bio chromatography separation technology, centrifugal separation Advanced technologies such as organic solvent classification and precipitation have realized automation, intelligence and digitization of production, and embarked on a road of original innovation and introduction of digestion and absorption innovation.

Management advantages: after years of exploration, the company has established a management team of the same mind and morality. In 2002, it was transformed into a holding company. The parent company was transformed into a group company with "top and bottom head" mainly focusing on management strategy and investment management. The subsidiary companies manage production and business operation, and the operation is formulated by their management team and independently bear legal responsibilities. Based on the parent subsidiary company, the paper optimizes and adjusts the organizational structure and post responsibilities. The core is the "two points" mode of "decentralized governance and hierarchical control". It is specialized and standardized in production, technology, R & D, sales, human resources and operation, fully mobilize the enthusiasm of all levels of management personnel, and effectively improve the management level and efficiency of the company.

Capital advantage: the company has established the double round drive growth mode of "industry + finance", which helps the development of real industry with financial advantages. The company has always been based on the pharmaceutical industry for development, and has become the first largest shareholder of GF Securities through investment in equity and timely market value management. Through equity investment, it has become the second shareholder of first medicine, the fifth shareholder of Nanjing Pharmaceutical, the top 10 shareholders of Liaoning Chengda and some listed companies in pharmaceutical industry invested, Meanwhile, we will cooperate with GF Sindh to establish funds to optimize pharmaceutical enterprises to invest, and develop business cooperation opportunities with equity investment as the link. The development path of the company, which is a combination of production and finance, is conducive to the company's sustainable and stable progress.

The company's products include "Anshen Bunao liquid", "RNA II for injection", "Xiaoniu spleen extract injection", "Xuefu Zhuyu oral liquid", "Naoxinshu oral liquid", "xiaochaigui Jiere oral liquid", "Yangxue drink oral liquid", "Xinnaoshutong Capsule", "Lingbei Zhike syrup", "Linaoxin capsule", "Shaowei Zhuyu Granule", "Shenfukang tablet" "Rice aminopyrine", "compound diisopropylamine chloride injection", "gestational Kang Granule", "Gentongping pill", "stretching tendon tablet", "altalek capsule", "deer tire Granule", "adenosine monophosphate for injection", "paediatrol Huang nanamin Granule", "Zhongfeng reengineering pill" have been widely praised by the market for its stable quality and obvious curative effect, It has promoted the continuous development and growth of the company's pharmaceutical industry.

The company adheres to the core values of "focusing on people and focusing on medicine", adheres to the development strategy of pharmaceutical industry, which is advancing in the same way as "large variety group and multi variety group", adheres to the development road driven by "industry + finance", complies with the development trend of pharmaceutical industry, actively gives full play to its own advantages, tamps the situation of steady development, and strives to achieve "providing safety, reliability for society The enterprise mission of "reassuring medicine".

Name: Jilin Aodong Pharmaceutical Group Co., Ltd

Address: No. 2158 Aodong street, Dunhua, Jilin Province

Post code: 133700

Tel: 0433-6238973

>> tungsten carbide rings silver